Literature DB >> 7605658

Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour.

T I Andersen1, E Paus, J M Nesland, S J McKenzie, A L Børresen.   

Abstract

The level of a c-erbB-2 related protein was determined in sera from 168 breast carcinoma patients, 12 females with benign breast disease, and 66 female controls using an ELISA (enzyme linked immunosorbent assay) kit. Elevated c-erbB-2 related protein level was detected in one of 13 preoperative sera (8%), two of 62 postoperative sera from patients without recurrent disease (3%), and 55 of 93 sera collected at recurrent disease (59%). Elevated serum levels were detected significantly more often in patients with distant metastases than in patients with recurrent disease restricted to loco-regional areas (68% versus 19%). Presence of elevated serum level was associated with ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. None of the patients who had normal ERBB2 gene copy number in tumour had elevated serum levels. Although the usefulness in postoperative prediction of the presence of micrometastases is somewhat questionable, the results suggest c-erbB-2 related protein to represent a novel tumour marker in serum and other body fluids from breast cancer patients at the time of diagnosis and during treatment monitoring.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605658     DOI: 10.3109/02841869509094014

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  14 in total

1.  Prognostic significance of serum c-erbB-2 protein in breast cancer patients.

Authors:  P C Willsher; J Beaver; S Pinder; J A Bell; I O Ellis; R W Blamey; J F Robertson
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Plasma bcl-2 and nitric oxide: possible prognostic role in patients with metastatic breast cancer.

Authors:  H E Gaballah; I Abdel Salam; N Abdel Wahab; O M Mansour
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

3.  Serum HER2 levels determined by two methods in patients with metastatic breast cancer.

Authors:  Naoki Hayashi; Seigo Nakamura; Yasuharu Tokuda; Hiroshi Yagata; Atsushi Yoshida; Hidekazu Ota; Gabriel N Hortobagyi; Massimo Cristofanilli; Naoto T Ueno
Journal:  Int J Clin Oncol       Date:  2011-05-25       Impact factor: 3.402

Review 4.  Challenges in the clinical utility of the serum test for HER2 ECD.

Authors:  Lian Lam; Nicholas McAndrew; Marla Yee; Ting Fu; Julia C Tchou; Hongtao Zhang
Journal:  Biochim Biophys Acta       Date:  2012-04-03

5.  ErbB2 immune response in breast cancer patients with soluble receptor ectodomain.

Authors:  V Visco; R Bei; E Moriconi; W Gianni; M H Kraus; R Muraro
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

6.  HER-2 gene amplification can be acquired as breast cancer progresses.

Authors:  Songdong Meng; Debasish Tripathy; Sanjay Shete; Raheela Ashfaq; Barbara Haley; Steve Perkins; Peter Beitsch; Amanullah Khan; David Euhus; Cynthia Osborne; Eugene Frenkel; Susan Hoover; Marilyn Leitch; Edward Clifford; Ellen Vitetta; Larry Morrison; Dorothee Herlyn; Leon W M M Terstappen; Timothy Fleming; Tanja Fehm; Thomas Tucker; Nancy Lane; Jianqiang Wang; Jonathan Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-11       Impact factor: 11.205

7.  Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.

Authors:  Sumit Isharwal; Michael Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin; Robert W Veltri
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

8.  Pilot study of the clinical significance of serum and urinary her-2/neu protein in bladder cancer patients.

Authors:  Taek Sang Kim; Hyun Yul Rhew; Hyun Yong Hwang
Journal:  Korean J Urol       Date:  2011-12-20

Review 9.  Biomarkers of gene expression: growth factors and oncoproteins.

Authors:  P W Brandt-Rauf
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

10.  Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.

Authors:  Tanja Fehm; Sven Becker; Silke Duerr-Stoerzer; Karl Sotlar; Volkmar Mueller; Diethelm Wallwiener; Nancy Lane; Erich Solomayer; Jonathan Uhr
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.